|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models显示文摘AIM To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma(HCC) patients after liver transplant.METHODS BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein(AFP), Lens culinaris agglutinin-reactive AFP(AFP-L3), and des-gammacarboxyprothrombin(DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios(HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42(1.18-5.00), 1.86(0.98-3.52), and 2.83(1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48(1.15-1.91) and 1.59(1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45(1.06-1.98) and 1.38(1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65,0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant(S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter(S-LAD). | Nicha Wongjarupong Gabriela M Negron-Ocasio Roongruedee Chaiteerakij Benyam D Addissie Essa A Mohamed Kristin C Mara William S Harmsen J Paul Theobald Brian E Peters Joseph G Balsanek Melissa M Ward Nasra H Giama Sudhakar K Venkatesh Denise M Harnois Michael R Charlton Hiroyuki Yamada Alicia Algeciras-Schimnich Melissa R Snyder Terry M Therneau Lewis R Roberts | 2018 | World Journal of Gastroenterology2018，24，12： | 5 |
| 2 | Efficacy of Transoral Fundoplication vs Omeprazole for Treatment of Regurgitation in a Randomized Controlled Trial显示文摘 | John G. Hunter Peter J. Kahrilas Reginald C.W. Bell Erik B. Wilson Karim S. Trad James P. Dolan Kyle A. Perry Brant K. Oelschlager Nathaniel J. Soper Brad E. Snyder Miguel A. Burch William Scott Melvin Kevin Reavis Daniel G. Turgeon Eric S. Hungness Brian | 2014 | Gastroenterology2014，，： | 2 |
| 3 | Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness显示文摘AIM:To study the safety and effectiveness associated with accelerated infliximab infusion protocols in patients with inflammatory bowel disease(IBD).METHODS:Original protocols and infusion rates were developed for the administration of infliximab over 90-min and 60-min.Then the IBD patients on stable maintenance infliximab therapy were offered accelerated infusions.To be eligible for the study,patients needed a minimum of four prior infusions.An initial infusion of 90-min was given to each patient;those tolerating the accelerated infusion were transitioned to a 60-min infusion protocol at their next and all subsequent visits.Any patient having significant infusion reactions would be reverted to the standard 120-min protocol.A change in a patient's dose mandated a single 120-min infusion before accelerated infusions could be administered again.RESULTS:The University of Virginia Medical Center's Institutional Review Board approved this study.Fifty IBD patients treated with infliximab 5mg/kg,7.5mg/kg and 10mg/kg were offered accelerated infusions.Forty-six patients consented to participate in the study.Nineteen(41.3%) were female,five(10.9%) were African American and nine(19.6%) had ulcerative colitis.The mean age was 42.6 years old.Patients under age 18 were excluded.Ten patients used immunosuppressive drugs concurrently out of which six were taking azathioprine,three were taking 6-mercaptopurine and one was taking methotrexate.One of the 46 study patients used corticosteroid therapy for his IBD.Seventeen of the patients used prophylactic medications prior to receiving infusions;six patients received corticosteroids as pre-medication.Four patients had a history of distant transfusion reactions to infliximab.These reactions included shortness of breath,chest tightness,flushing,pruritus and urticaria.These patients all took prophylactic medications before receiving infusions.46 patients(27 males and 19 females) received a total of fifty 90-min infusions and ninety-three 60-min infusions.No infusion reactions were reported.There were no adverse events,including drug-related infections.None of the patients developed cancer of any type during the study timeframe.Total cost savings for administration of the both 90-min and 60-min accelerated infusions compared to standard 120-min infusions was estimated to be $53 632($116 965 vs $63 333,P=0.001).One hundred and eighteen hours were saved in the administration of the accelerated infusions(17 160 min vs 10 080 min,P=0.001).In the study population,overweight females [body mass index(BMI)>25.00kg/m2] were found to have statistically higher BMIs than overweight males(mean BMI 35.07±2.66kg/m2 vs 30.08±0.99kg/m2,P=0.05),finding which is of significance since obesity was described as being one of the risk factors for Crohn's disease.CONCLUSION:We are the first US group to report substantial cost savings,increased safety and patient satisfaction associated with accelerated infliximab infusion. | John McConnell Simona Parvulescu-Codrea Brian Behm Beth Hill Elizabeth Dunkle Karen Finke Kathryn Snyder Anne Tuskey Debbie Cox Beth Woodward | 2012 | World Journal of Gastrointestinal Pharmacology and Therapeutics2012，3，5： | 2 |
| 4 | Bone Tissue Engineering Using Human Mesenchymal Stem Cells: Effects of Scaffold Material and Medium Flow显示文摘 | Lorenz Meinel Vassilis Karageorgiou Robert Fajardo Brian Snyder Vivek Shinde-Patil Ludwig Zichner David Kaplan Robert Langer Gordana Vunjak-Novakovic | 2004 | Annals of Biomedical Engineering2004，，1： | 2 |
| 5 | Beyond resource-based theory: further avenues for industrial-organizational psycholo- gy Ventures Into Strategic Management显示文摘 | BRIAN D CAWLEY PETER J SNYDER | 2012 | Industfial and organizational psychology2012，5，1： | 1 |
| 6 | A comparison of offshore wind power development in europe and the U.S.: Patterns and drivers of development显示文摘 | Brian Snyder Mark J. Kaiser | 2009 | Applied Energy2009，，10： | 1 |
| 7 | Bone Tissue Engineering Using Human Mesenchymal Stem Cells: Effects of Scaffold Material and Medium Flow显示文摘 | Lorenz Meinel Vassilis Karageorgiou Robert Fajardo Brian Snyder Vivek Shinde-Patil Ludwig Zichner David Kaplan Robert Langer Gordana Vunjak-Novakovic | 2004 | Annals of Biomedical Engineering2004，，1： | 1 |
| 8 | A Clinically Applicable Porcine Model of Septic and Ischemia/Reperfusion-Induced Shock and Multiple Organ Injury显示文摘 | Brian D. Kubiak Scott P. Albert Louis A. Gatto Christopher J. Vieau Shreyas K. Roy Kathleen P. Snyder Kristopher G. Maier Gary F. Nieman | 2011 | Journal of Surgical Research2011，，1： | 1 |
| 9 | Ecological and economic cost-benefit analysis of offshore wind energy显示文摘 | Brian Snyder Mark J Kaiser | 2009 | Renewable Energy2009，34，6： | 1 |
| 10 | Peritoneal Negative Pressure Therapy Prevents Multiple Organ Injury in a Chronic Porcine Sepsis and Ischemia/Reperfusion Model显示文摘 | Brian D. Kubiak Scott P. Albert Louis A. Gatto Kathleen P. Snyder Kristopher G. Maier Christopher J. Vieau Shreyas Roy Gary F. Nieman | 2010 | Shock2010，，5： | 1 |
| 11 | Performance of pyrolyzed photoresist carbon films in a microchip capillary electrophoresis device with sinusoidal voltammetric detection显示文摘 | Snyder Brian Richard L | 2003 | Anal Chem2003，75，： | 1 |
| 12 | Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells显示文摘 | Omkar U. Kawalekar Roddy S. O’Connor Joseph A. Fraietta Lili Guo Shannon E. McGettigan Avery D. Posey Prachi R. Patel Sonia Guedan John Scholler Brian Keith Nathaniel Snyder Ian Blair Michael C. Milone Carl H. June | 2016 | Immunity2016，，2： | 1 |
| 13 | Vibration and flutter characteristics of a folding wing显示文摘 | Matthew P Snyder Brian Sanders Franklin E Eastep | | 0，，03： | 1 |
| 14 | Biologically Enabled Syntheses of Nanostructured 3-D Sensor Materials:the Potential for 3-D Genetically Engineered Microdevices (3-D GEMs)显示文摘Three-dimensional (3-D)self-assembly of nanos- tructures and nanodevices on a large scale remains a grand quest for mankind.Freestanding nanostructured assemblies with controlled 3-D shapes can exhibit attractive properties for sensor and other applications. Protocols for 3-D self-assembly that can be scaled up for mass production on a large up to tonnage)scale, while preserving morphological features on a small (down to nanometer)scale,are needed to allow for widespread use of 3-D nanostructures in advanced devices.However,these often conflicting requirements of scalability and precision pose a difficult challenge for synthetic (man-made)processing routes. | Kenneth H. Sandhage Samuel Shian Christopher S. Gaddis Michael R. Weatherspoon Ye Cai Sehoon Yoo Michael S. Haluska Robert L. Snyder Ying Liu Meilin Liu Nicholas Ferrell Derek J. Hansford Mark Hildebrand Brian Palenik | 2006 | 稀有金属材料与工程2006，35，A03： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员